Question explored with the scientific record
Are there any safe drugs to build bone in osteoporosis and what is the current risk benefit analysis for asymptomatic patients with osteoporosis
For an asymptomatic patient with osteoporosis, the decision to start medication is a bet on a future fracture you may never have, against side effects you definitely take on.
The best evidence comes from a 2026 meta-analysis of 24 randomized trials in postmenopausal women, which found that bisphosphonates reduce the risk of a second vertebral fracture by about 40-60% over 1.5 to 3 years [1]. Non-bisphosphonates like denosumab and teriparatide showed a 30-50% reduction [1]. Bone mineral density (BMD) increased by 3-7% with bisphosphonates and 3-5% with non-bisphosphonates [1]. The same analysis reported low adverse-event risk ratios for both drug classes [1].
However, a 2019 review of eight trials found one study where the treatment group actually had more vertebral fractures than the placebo group (20% vs 16%) [2]. This is a red flag that the effect is not universal. The 2026 meta-analysis also showed that for hip fractures specifically, the benefit was not statistically significant [1]. This matters because hip fractures are the most devastating outcome.
For an asymptomatic patient, the absolute risk of fracture is lower than for someone who has already broken a bone. The number needed to treat (NNT) to prevent one fracture is therefore higher, and the risk-benefit equation shifts. The drugs carry real risks: denosumab has been linked to a numerical increase in serious infections requiring hospitalization (3.2% vs 0% in one phase 2 trial) [4], and romosozumab carries a boxed warning for cardiovascular events [6]. The long-term safety data for these drugs is limited to a few years of follow-up [2].
| Drug Class | Vertebral Fracture Reduction | Hip Fracture Reduction (statistical significance) | Key Safety Signal |
|---|---|---|---|
| Bisphosphonates | 40-60% [1] | Not significant [1] | GI upset, rare jaw necrosis |
| Denosumab | 68% [4] | Significant (p=0.04) [3] | Infection signal [4] |
| Romosozumab | 73% [7] | Not powered [5] | Cardiovascular warning [6] |
My call: For an asymptomatic patient, the evidence for preventing hip fractures—the outcome that matters most—is weak. The drugs increase BMD and reduce vertebral fractures, but the absolute benefit is small and must be weighed against the certainty of side effects and the uncertainty of long-term safety. Confidence: moderate.
Sources used 7
-
Pharmacological Management of Bone Metabolism in Post-Menopausal Women: A Meta-Analysis of Randomized Controlled Trials on Bisphosphonates and Alternative Therapies for Secondary Osteoporotic Fracture Prevention
A meta-analysis of 24 randomized controlled trials found high-to-moderate quality evidence that most bisphosphonates and non-bisphosphonates significantly reduce secondary vertebral fracture risk and increase bone mineral density in postmenopausal women with osteoporosis, with l…
DOI: 10.31083/ijp45195 -
Bisphosphonates in Postmenopausal Women with Osteoporosis to Prevent Future Fractures
A review of eight randomized placebo-controlled trials concluded that bisphosphonate therapy in postmenopausal women with osteoporosis increases bone mineral density and, in four of five fracture-reporting trials, reduces future fracture risk, despite one conflicting trial.
DOI: 10.23880/jobd-16000179 -
The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab
This review describes denosumab, a RANKL inhibitor, its mechanism and extensive clinical evidence in postmenopausal osteoporosis, highlighting its fracture risk reduction, sustained bone density gains, and safety profile compared with and beyond traditional antiresorptives, base…
DOI: 10.3109/09513590.2014.892067 -
Denosumab in postmenopausal osteoporosis: what the clinician needs to know
This narrative review reports that denosumab 60 mg every 6 months increases BMD and reduces bone turnover markers in postmenopausal women, reduces vertebral, hip, and nonvertebral fractures, and has a safety profile generally similar to placebo and alendronate.
DOI: 10.1177/1759720x09343221 -
Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential
Anti-sclerostin antibodies rapidly stimulate bone formation and markedly increase bone mineral density, with vertebral fracture risk reductions demonstrated in major trials, though safety signals and variable nonvertebral fracture results temper enthusiasm and guide retreatment …
DOI: 10.1177/1759720x17726744 -
Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
A narrative review synthesizing efficacy and safety data for romosozumab in postmenopausal osteoporosis, highlighting strong antifracture efficacy and substantial BMD gains but with signals of increased cardiovascular risk that warrant cautious patient selection and sequencing w…
DOI: 10.1177/17455057221125577 -
Osteoporosis Management
A clinical update summarizing recent osteoporosis management evidence, including oral contraceptives for anorexia nervosa-related bone loss and sequential anabolic–antiresorptive therapies (abaloparatide, romosozumab, denosumab, alendronate) that reduce fracture risk.
DOI: 10.1089/jwh.2019.8195